Search research articles
Contact Us
Filters
Showing results (411-420 of 713) with videos related to
Page
of 72
Sort By:
American Journal of Clinical Pathology
|
October 12, 2002
Differences in CD33 intensity between various myeloid neoplasms
Iman Jilani, Elihu Estey, Yang Huh, et al.
American Journal of Hematology
|
May 15, 2021
Inotuzumab ozogamicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia
Nitin Jain, Abhishek Maiti, Farhad Ravandi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 4, 2005
Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate
Jorge Cortes, Moshe Talpaz, Susan O'Brien, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
September 25, 2013
Similar outcome of patients with chronic myeloid leukemia treated with imatinib in or out of clinical trials
Musa Yilmaz, Hagop Kantarjian, Elias Jabbour, et al.
Cancer
|
May 28, 2024
Results of ponatinib as frontline therapy for chronic myeloid leukemia in chronic phase
Fadi G Haddad, Koji Sasaki, Lewis Nasr, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 26, 2009
Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome
Hagop Kantarjian, Guillermo Garcia-Manero, Susan O'Brien, et al.
Leukemia & Lymphoma
|
October 6, 2015
Incidence and management of myelosuppression in patients with chronic- and accelerated-phase chronic myeloid leukemia treated with omacetaxine mepesuccinate
Luke Akard, Hagop M Kantarjian, Franck E Nicolini, et al.
Cancer
|
May 27, 2003
Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders
Jorge Cortes, Francis Giles, Susan O'Brien, et al.
Cancer
|
April 25, 2003
Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia
Hagop Kantarjian, Moshe Talpaz, Susan O'Brien, et al.
Blood
|
August 17, 2012
Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation
Jorge Cortes, Jeff H Lipton, Delphine Rea, et al.
Page
of 72
Search research articles
Search
Showing results (411-420 of 713) with videos related to
Sort By:
Page
of 72
American Journal of Clinical Pathology
|
October 12, 2002
Differences in CD33 intensity between various myeloid neoplasms
Iman Jilani, Elihu Estey, Yang Huh, et al.
American Journal of Hematology
|
May 15, 2021
Inotuzumab ozogamicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia
Nitin Jain, Abhishek Maiti, Farhad Ravandi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 4, 2005
Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate
Jorge Cortes, Moshe Talpaz, Susan O'Brien, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
September 25, 2013
Similar outcome of patients with chronic myeloid leukemia treated with imatinib in or out of clinical trials
Musa Yilmaz, Hagop Kantarjian, Elias Jabbour, et al.
Cancer
|
May 28, 2024
Results of ponatinib as frontline therapy for chronic myeloid leukemia in chronic phase
Fadi G Haddad, Koji Sasaki, Lewis Nasr, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 26, 2009
Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome
Hagop Kantarjian, Guillermo Garcia-Manero, Susan O'Brien, et al.
Leukemia & Lymphoma
|
October 6, 2015
Incidence and management of myelosuppression in patients with chronic- and accelerated-phase chronic myeloid leukemia treated with omacetaxine mepesuccinate
Luke Akard, Hagop M Kantarjian, Franck E Nicolini, et al.
Cancer
|
May 27, 2003
Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders
Jorge Cortes, Francis Giles, Susan O'Brien, et al.
Cancer
|
April 25, 2003
Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia
Hagop Kantarjian, Moshe Talpaz, Susan O'Brien, et al.
Blood
|
August 17, 2012
Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation
Jorge Cortes, Jeff H Lipton, Delphine Rea, et al.
Page
of 72